Literature DB >> 24658821

A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma.

Neha Korde1, Mattias Carlsten2, Min-Jung Lee3, Alex Minter4, Esther Tan4, Mary Kwok4, Elisabet Manasanch1, Manisha Bhutani1, Nishant Tageja1, Mark Roschewski1, Adriana Zingone1, Rene Costello1, Marcia Mulquin1, Diamond Zuchlinski1, Irina Maric5, Katherine R Calvo5, Raul Braylan5, Prashant Tembhare6, Constance Yuan6, Maryalice Stetler-Stevenson6, Jane Trepel3, Richard Childs2, Ola Landgren7.   

Abstract

Entities:  

Keywords:  HLA-C binding KIR2D reports; IPH2101; KIR2D blockade; NK-cell function; clinical response; smoldering multiple myeloma

Mesh：

Substances：

Year:  2014        PMID： 24658821      PMCID： PMC4040899          DOI： 10.3324/haematol.2013.103085

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  14 in total

Review 1.  The role of natural killer cells in immunity against multiple myeloma.

Authors:  James Godfrey; Don M Benson
Journal:  Leuk Lymphoma       Date:  2012-04-19

2.  IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect.

Authors:  Don M Benson; Courtney E Bakan; Shuhong Zhang; Shauna M Collins; Jing Liang; Shivani Srivastava; Craig C Hofmeister; Yvonne Efebera; Pascale Andre; Francois Romagne; Mathieu Bléry; Cécile Bonnafous; Jianying Zhang; David Clever; Michael A Caligiuri; Sherif S Farag
Journal:  Blood       Date:  2011-10-26       Impact factor: 22.113

3.  Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma.

Authors:  María-Victoria Mateos; Miguel-Teodoro Hernández; Pilar Giraldo; Javier de la Rubia; Felipe de Arriba; Lucía López Corral; Laura Rosiñol; Bruno Paiva; Luis Palomera; Joan Bargay; Albert Oriol; Felipe Prosper; Javier López; Eduardo Olavarría; Nuria Quintana; José-Luis García; Joan Bladé; Juan-José Lahuerta; Jesús-F San Miguel
Journal:  N Engl J Med       Date:  2013-08-01       Impact factor: 91.245

4.  Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1.

Authors:  S Vincent Rajkumar; Jean-Luc Harousseau; Brian Durie; Kenneth C Anderson; Meletios Dimopoulos; Robert Kyle; Joan Blade; Paul Richardson; Robert Orlowski; David Siegel; Sundar Jagannath; Thierry Facon; Hervé Avet-Loiseau; Sagar Lonial; Antonio Palumbo; Jeffrey Zonder; Heinz Ludwig; David Vesole; Orhan Sezer; Nikhil C Munshi; Jesus San Miguel
Journal:  Blood       Date:  2011-02-03       Impact factor: 22.113

5.  Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch after dose-reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma.

Authors:  Nicolaus Kröger; Bronwen Shaw; Simona Iacobelli; Tatjana Zabelina; Karl Peggs; Avichai Shimoni; Arnon Nagler; Thomas Binder; Thomas Eiermann; Alejandro Madrigal; Rainer Schwerdtfeger; Michael Kiehl; Herbert Gottfried Sayer; Jörg Beyer; Martin Bornhäuser; Francis Ayuk; Axel Rolf Zander; David I Marks
Journal:  Br J Haematol       Date:  2005-06       Impact factor: 6.998

6.  New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells.

Authors:  Ernesto Pérez-Persona; María-Belén Vidriales; Gema Mateo; Ramón García-Sanz; Maria-Victoria Mateos; Alfonso García de Coca; Josefina Galende; Guillermo Martín-Nuñez; José M Alonso; Natalia de Las Heras; José M Hernández; Alejandro Martín; Consuelo López-Berges; Alberto Orfao; Jesús F San Miguel
Journal:  Blood       Date:  2007-06-18       Impact factor: 22.113

7.  Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation.

Authors:  Jumei Shi; Guido Tricot; Susann Szmania; Nancy Rosen; Tarun K Garg; Priyangi A Malaviarachchi; Amberly Moreno; Bo Dupont; Katharine C Hsu; Lee Ann Baxter-Lowe; Michele Cottler-Fox; John D Shaughnessy; Bart Barlogie; Frits van Rhee
Journal:  Br J Haematol       Date:  2008-10-16       Impact factor: 6.998

8.  HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells.

Authors:  Ennio Carbone; Paola Neri; Maria Mesuraca; Mariateresa T Fulciniti; Takemi Otsuki; Daniela Pende; Veronika Groh; Thomas Spies; Giuditta Pollio; David Cosman; Lucio Catalano; Pierfrancesco Tassone; Bruno Rotoli; Salvatore Venuta
Journal:  Blood       Date:  2004-08-24       Impact factor: 22.113

9.  Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma.

Authors:  Angela Dispenzieri; Robert A Kyle; Jerry A Katzmann; Terry M Therneau; Dirk Larson; Joanne Benson; Raynell J Clark; L Joseph Melton; Morie A Gertz; Shaji K Kumar; Rafael Fonseca; Diane F Jelinek; S Vincent Rajkumar
Journal:  Blood       Date:  2007-10-17       Impact factor: 22.113

10.  Smoldering multiple myeloma: natural history and recognition of an evolving type.

Authors:  L Rosiñol; J Bladé; J Esteve; M Aymerich; M Rozman; S Montoto; E Giné; E Nadal; X Filella; R Queralt; A Carrió; E Montserrat
Journal:  Br J Haematol       Date:  2003-11       Impact factor: 6.998
View more
  55 in total

1.  Targeting KIR Blockade in Multiple Myeloma: Trouble in Checkpoint Paradise?

Authors:  Martin Felices; Jeffrey S Miller
Journal:  Clin Cancer Res       Date:  2016-07-18       Impact factor: 12.531

Review 2.  Strategies to enhance NK cell function for the treatment of tumors and infections.

Authors:  Jacquelyn Freund-Brown; Leilani Chirino; Taku Kambayashi
Journal:  Crit Rev Immunol       Date:  2018       Impact factor: 2.214

Review 3.  Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakens.

Authors:  Richard W Childs; Mattias Carlsten
Journal:  Nat Rev Drug Discov       Date:  2015-05-22       Impact factor: 84.694

4.  Emerging immune targets for the treatment of multiple myeloma.

Authors:  Atif Sohail; Adeela Mushtaq; Ahmad Iftikhar; Zabih Warraich; Sandra E Kurtin; Pavan Tenneti; Ali McBride; Faiz Anwer
Journal:  Immunotherapy       Date:  2018-02-01       Impact factor: 4.196

Review 5.  Trial watch: Immune checkpoint blockers for cancer therapy.

Authors:  Claire Vanpouille-Box; Claire Lhuillier; Lucillia Bezu; Fernando Aranda; Takahiro Yamazaki; Oliver Kepp; Jitka Fucikova; Radek Spisek; Sandra Demaria; Silvia C Formenti; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2017-08-31       Impact factor: 8.110

Review 6.  Haematological malignancies: at the forefront of immunotherapeutic innovation.

Authors:  Pavan Bachireddy; Ute E Burkhardt; Mohini Rajasagi; Catherine J Wu
Journal:  Nat Rev Cancer       Date:  2015-03-19       Impact factor: 60.716

Review 7.  Killers 2.0: NK cell therapies at the forefront of cancer control.

Authors:  Jonathan J Hodgins; Sarwat T Khan; Maria M Park; Rebecca C Auer; Michele Ardolino
Journal:  J Clin Invest       Date:  2019-09-03       Impact factor: 14.808

Review 8.  Natural killer cells in hepatocellular carcinoma: current status and perspectives for future immunotherapeutic approaches.

Authors:  Min Yu; Zonghai Li
Journal:  Front Med       Date:  2017-08-05       Impact factor: 4.592

Review 9.  Immune checkpoint blockade for hematologic malignancies: a review.

Authors:  Matthew J Pianko; Yuzhou Liu; Srishti Bagchi; Alexander M Lesokhin
Journal:  Stem Cell Investig       Date:  2017-04-19

Review 10.  Exploring the NK cell platform for cancer immunotherapy.

Authors:  Jacob A Myers; Jeffrey S Miller
Journal:  Nat Rev Clin Oncol       Date:  2020-09-15       Impact factor: 66.675
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.